CTLA4 and neoplasm: The combination of radiotherapy and anti-CTLA-4 increases the diversity of TIL TCR repertoire, leading to increased tumour control in vivo; however, these tumours remain dominated by a small number of high-frequency T-cell clones (30, 32).